Gland Pharma Shares Surge After Announcing Strong Q3FY26 Results

Gland Pharma Ltd has reported a robust financial performance for the third quarter ended December 31, 2025, characterised by double-digit growth across its primary metrics. The company’s quarterly revenue surged by 22 per cent year-on-year, while the nine-month revenue figures saw a steady 12 per cent increase. This momentum translated effectively to the bottom line, with adjusted Profit After Tax (PAT) climbing 37 per cent for the quarter and 33 per cent for the nine months. These gains were supported by increased volumes from capacity expansion, successful new Service ramp-ups, and strategic cost-reduction initiatives that enhanced the overall margin profile.

The quarter was marked by a significant commitment to long-term growth through intensified Research and Development. R&D investments rose to Rs 650 million, up from Rs 437 million in the previous year, now representing 5.4 per cent of total revenue. This capital was primarily deployed toward complex Service development and an aggressive filing schedule. The company successfully launched nine molecules in the United States—including Argatroban and Doxycycline—and expanded its footprint in other regulated markets like Europe and Canada with two additional launches.

Operational highlights include a major focus on high-value segments, specifically Drug Device Combinations (DDCs) and Ready-to-Use (RTU) bags. Gland Pharma launched its first partnered GLP-1, Liraglutide, in the US and is currently scaling its pen and cartridge capacity from 40 million to 140 million units to meet rising demand. Furthermore, the RTU infusion bag portfolio now addresses a market opportunity of approximately USD 685 million in the US, with 16 approvals already secured and 13 more products currently in development.

In the manufacturing and contract services domain, Gland Pharma secured a new CMO contract with a major pharmaceutical firm for a complex Nano Drug Delivery System used in Oncology. This partnership provides clear revenue visibility given the Service's established global commercial status. Expansion remains a priority at European sites; the Fontenay facility is adding a high-capacity ampoule line set to produce 30 million units by 2027, while the Braine-l’Alleud site is preparing for a new combo line for prefilled syringes and cartridges in 2026.

The Cenexi business segment also showed positive trends, with Q3 FY26 revenue reaching €50 million, a 39 per cent increase year-on-year. While EBITDA for this segment remains lean, the transition to positive territory—reaching EURO 1.4 million for the quarter—indicates a successful turnaround compared to previous losses. With a cumulative total of 384 ANDA filings in the U.S. and a growing pipeline of 15 co-development products, Gland Pharma appears well-positioned to maintain its trajectory of profitable growth through the end of the fiscal year.

About Gland Pharma Limited (BSE: 543245, NSE: GLAND)

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and has an excellent track record in the development, manufacturing, and marketing of sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilised vials, dry powders, infusions, oncology, and ophthalmic solutions, and also enjoys the distinction of having pioneered Heparin technology in India.

Disclaimer: The article is for informational purposes only and not investment advice.